CL2015003211A1 - Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. - Google Patents

Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Info

Publication number
CL2015003211A1
CL2015003211A1 CL2015003211A CL2015003211A CL2015003211A1 CL 2015003211 A1 CL2015003211 A1 CL 2015003211A1 CL 2015003211 A CL2015003211 A CL 2015003211A CL 2015003211 A CL2015003211 A CL 2015003211A CL 2015003211 A1 CL2015003211 A1 CL 2015003211A1
Authority
CL
Chile
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
CL2015003211A
Other languages
English (en)
Inventor
Medellin Jorge Fernando Cantu
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of CL2015003211A1 publication Critical patent/CL2015003211A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINACIÓN FARMACEUTICA SINERGÍSTICA DE PARACETAMOL/CELECOXIB Y SU USO PARA EL TRATAMIENTO DEL DOLOR INFLAMATORIO.
CL2015003211A 2013-07-11 2015-10-30 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. CL2015003211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (es) 2013-07-11 2013-07-11 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Publications (1)

Publication Number Publication Date
CL2015003211A1 true CL2015003211A1 (es) 2016-04-29

Family

ID=52279400

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003211A CL2015003211A1 (es) 2013-07-11 2015-10-30 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Country Status (8)

Country Link
CL (1) CL2015003211A1 (es)
CR (1) CR20160021A (es)
CU (1) CU24440B1 (es)
DO (1) DOP2016000008A (es)
EC (1) ECSP16005679A (es)
MX (1) MX366118B (es)
PE (2) PE20160239A1 (es)
WO (2) WO2015004505A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070251A1 (en) * 2002-02-19 2003-08-28 Adcock Ingram Limited Pharmaceutical combinations of cox-2 inhibitors and opiates
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Also Published As

Publication number Publication date
ECSP16005679A (es) 2017-08-31
MX366118B (es) 2019-06-27
MX2015013911A (es) 2015-12-08
PE20160239A1 (es) 2016-05-13
DOP2016000008A (es) 2016-03-15
PE20170305A1 (es) 2017-04-21
CU20160002A7 (es) 2016-06-29
CU24440B1 (es) 2019-09-04
WO2015004634A3 (es) 2015-04-09
WO2015004505A1 (es) 2015-01-15
WO2015004634A2 (es) 2015-01-15
CR20160021A (es) 2016-04-08

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CL2015002897A1 (es) Inhibidores de bace1
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
ES2970224T3 (es) Tinostamustina para su uso en el tratamiento del sarcoma
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
ES2970485T3 (es) Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina